and Drug Administration (CFDA), which took around 2 months, that we have got CFDA in early 2018. Sales by product category Consolidated financial statements For the three months period ended March 31
. The other project was the property project for investment in the rental market i.e. Lumpini Township Rangsit-Khlong 1 Phase 3 (Building F). Around 80% of condominium units in three buildings was already
year where GWM manufactured and later distribute hemodialysis solution around the end of July 2017 which directly lead to increase in performance for the early of 2018. The company acquires GWM share
2017, the Group has revenue from construction contracts total of 1,019,29 Million Baht, or 56.50% compared with 2016, or increased around 367.99 Million Baht. This increased by revenue growth from
buying new agriculture machines. 2. Cost of sales of goods and Expenses 2.1. Cost of sales of goods for the 3-month period ended March 31, 2020 decreased from the same period of last year around 34.57% or
payment period with customer around 30 days to 45 days. o Inventories of Baht 20.35 Million, increased from the previous year of Baht 10.63 Million by purchasing during the period for projects on hand. Non
. Choice, Pet Select) and pet food (Maria). The Company has discontinued distributorship of Nabota, Aesthetic Innovation Product from Korea, around end of 2019, therefore, there will no revenue shown in 1st
performance. The backlog was around 10% of the total sales that lead to less risk under cost fluctuations. The Company has also managed the risk for exchange rate by forward contract. Please be informed
recurring revenue remains constant at around 77.8% (Q3 2018: 78.2%) versus a non-recurring revenue of 22.2% (Q3 2018: 21.8%). We have a growth in non-recurring revenue in HR Solution of 17.72mb due to the